Entera Bio bounds up on osteoporosis resultsEntera Bio surges to sensational highs, soaring around 70% in the first two hours of Wednesday trading on the back of strong results from its latest osteoporosis study, and closing up 45% to become TradingView's top gainer of the day.
Shares of clinical-stage biopharmaceutical company Entera Bio saw some great gains in morning trading after releasing mid-stage osteoporosis study data results that got the market buzzing. The Israeli firm focuses on developing orally-delivered large molecule therapeutics for medical needs that have not yet been met. The company is based in Jerusalem, and right now one of its top projects is the development of its osteoporosis treatment. Judging by today’s gains, things are clearly going well.
Prices first went crazy in March, after the biotech company released a positive initial analysis on one of its Osteoporosis studies. The disease affects around 5.3 million people above the age of 50 in the U.S., so you can see why people got excited. Prices lifted from $1.60 to highs of $10, closing at $6.90 two days later, more than double its starting point.
With the final data from that study now available, shares have seen another surge, closing at $6.50 on Wednesday.
Subscribe to Snaps
See the market snapshots that matter and nothing else – sent to your inbox daily. Designed to be read in 20 seconds or less.